DRUG DISCOVERY

More in DRUG DISCOVERY

• The Role of Data Science in Revolutionizing Personalized Medicine and Drug Discovery

  ​Genomic data holds immense promise in personalized medicine. Advances in DNA sequencing technologies have made it possible to decode an individual's entire genome, uncovering genetic variations that may influence disease susceptibility, drug metabolism, and treatment outcomes. Data science techniques enable the interpretation of this complex data, identifying genetic markers associated with specific diseases or drug responses.

  

• Experts discuss the role of AI/ML in drug discovery and innovations at REPharma Summit 2024

  The 4th edition of the REPharma Summit featured an insightful panel discussion titled "Deploying AI/ML for Drug Discovery & Biotechnology Innovations" where experts brought to the fore the transformative role AI/ML has played in the pharma industry.

  • Exclusive

  

• AI and ML is changing the game of drug discovery

  The integration of artificial intelligence (AI) and data-driven methodologies in drug discovery has the potential to revolutionize this paradigm, introducing speed, minimizing late-stage failures, improving efficiencies, and cost-effectiveness.

  • Exclusive

  

• Top 5 Technology Trends Shaping Modern Healthcare in 2024

  ​​The interconnection of healthcare with IT has gotten deeper than one could have ever imagined. In 2022, the global healthcare IT market size was valued at USD 174.3 billion, with an expected CAGR of 18.2% from 2023 to 2030, reaching USD 644.9 billion by 2030

  

• Thermo Fisher Scientific to buy Olink in $3.1 billion deal

  The deal lifted Olink's U.S.-listed shares nearly 67 per cent in early trading, while shares of Thermo Fisher were down over 1 per cent. Thermo Fisher has been struggling with softening demand for its life sciences offerings, which includes discovery and production of new drugs and vaccines, as its biotech clients face a funding crunch.

  

• Revvity launches SaaS platform to accelerate drug development

  The SaaS platform will integrate the Revvity Signals Notebook, VitroVivo, and Inventa applications into a single, robust solution to support the entire drug development process, from early research and in vitro testing and safety to early development as well as specialty chemicals new product development.

  

• Cutting-edge lab for research on biotechnology, drug discovery comes up in Vizag

  Such an ecosystem would enable start-ups, while suggesting that GITAM could allow the lab to be used by local universities and institutions for a nominal fee.

  

• Growth opportunities abound for organisations invested in drug, vaccine discovery and development

  Adaptive study designs, platform trial designs, companion diagnostics and precision medicine clinical trials are what are accelerating clinical development timelines for several therapeutic areas. India is adapting to the changes in the way clinical trials are run and a huge fillip to this happened during the COVID period.

  • Exclusive

  

• RePharma Summit: Innovations disrupting Indian pharma industry

  To decode the digital, technological and innovative disruptions in the pharmaceutical sector, ushered in by the entrepreneurial spirits of the veterans and experts of the industry, ETHealthworld is back with the third edition of RePharma Summit themed ‘The Future is NOW,’ with presenting partner Anervea, knowledge partner IBM, in association with Salesforce, gold partners Veeva and Wolters Kluwer, analytics partner Qlik Q, and supporting partners Zota Healthcare Ltd and Davaindia.

  • Exclusive

  

• Suven Life Sciences breathes new life into drug discovery plans

  The funding to keep his drug discovery pursuits alive may not be a problem, as Jasti in December last year sold his profitable contract development and manufacturing services (CDMO) venture Suven Pharmaceuticals to private equity firm Advent International for ₹6,313 crore.

  

• Biotech firms Redx Pharma and Jounce Therapeutics to merge in $425 mln deal

  Redx shareholders will receive 0.2105 Jounce share in exchange for each Redx share, and the combined company would be called Redx Inc and will be listed on Nasdaq. Redx shareholders will own about 63 per cent, while Jounce shareholders will own 37 per cent of the combined group, the statement added.